MLMin Liu

Min Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Bi Peng

    Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Qijia Yan

    Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Shuangshuang Zeng

    Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Yuan Cai

    Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Yuanliang Yan

    Department of Pharmacy, The Hunan Institute of Pharmacy Practice and Clinical Research, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Zhicheng Gong

    Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication

Latest Publications

  • Use of cucurbitacins for lung cancer research and therapy

    by Min Liu, Qijia Yan, Bi Peng, Yuan Cai, Shuangshuang Zeng, Zhijie Xu, Yuanliang Yan, Zhicheng Gong

    As the main substance in some traditional Chinese medicines, cucurbitacins have been used to treat hepatitis for decades in China. Currently, the use of cucurbitacins against cancer and other diseases has achieved towering popularity among researchers worldwide, as detailed in this review with summarized tables. Numerous studies have reported the potential tumor-killing activities of cucurbitacins in multiple aspects of human malignancies. Continuous research on its anticancer activity mechanisms also brings a glimmer of light to the treatment of patients with lung cancer. In line with the promising roles of cucurbitacins against cancer, through various molecular signaling pathways, it is justifiable to propose the use of cucurbitacins as a potential mainline chemotherapy before the onset and after the diagnosis of lung cancers. Here, this article mainly summarized the findings about the biological functions and underlying mechanisms of cucurbitacins on lung cancer pathogenesis and treatment. In addition, we also discussed the safety and efficacy of their application for further research and even clinical practice.